0000000000237071

AUTHOR

Jens Kuhle

showing 2 related works from this author

MSJ765666_supplementary_figure_1 – Supplemental material for Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in e…

2018

Supplemental material, MSJ765666_supplementary_figure_1 for Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis by Nelly Siller, Jens Kuhle, Muthuraman Muthuraman, Christian Barro, Timo Uphaus, Sergiu Groppa, Ludwig Kappos, Frauke Zipp and Stefan Bittner in Multiple Sclerosis Journal

FOS: Clinical medicine111702 Aged Health CareFOS: Health scienceshumanities110904 Neurology and Neuromuscular Diseases
researchProduct

Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.

2018

Background: Monitoring neuronal injury remains one key challenge in early relapsing-remitting multiple sclerosis (RRMS) patients. Upon axonal damage, neurofilament – a major component of the neuro-axonal cytoskeleton – is released into the cerebrospinal fluid (CSF) and subsequently peripheral blood. Objective: To investigate the relevance of serum neurofilament light chain (sNfL) for acute and chronic axonal damage in early RRMS. Methods: sNfL levels were determined in 74 patients (63 therapy-naive) with recently diagnosed clinically isolated syndrome (CIS) or RRMS using Single Molecule Array technology. Standardized 3 T magnetic resonance imaging (MRI) was performed at baseline and 1–3 con…

AdultMalePathologymedicine.medical_specialtyNeurofilamentMultiple SclerosisNeurofilament lightIntermediate FilamentsSeverity of Illness IndexDisease activity03 medical and health sciencesYoung Adult0302 clinical medicineNeuronal damageNeurofilament ProteinsMedicineHumans030212 general & internal medicineNeuronsbusiness.industryMultiple sclerosisNeurodegenerationBrainMiddle Agedmedicine.diseaseNeurologyBiomarker (medicine)FemaleNeurology (clinical)Atrophybusiness030217 neurology & neurosurgeryClinical progressionBiomarkersMultiple sclerosis (Houndmills, Basingstoke, England)
researchProduct